|
Base case analysis |
|||||
| Strategy |
Cost ($) |
Effectiveness (QALYs) |
Marginal Cost ($) |
Marginal Effectiveness (QALYs) |
Marg C/E ratio (Δ$/ΔQALYs) |
|
|
|||||
| rFVIIa |
$39,305 |
0. 40 |
|||
| Usual Care |
$40,359 |
0. 29 |
$1,053. 20 |
-0. 11 |
******** |
|
******** no mCER because rFVIIa dominates usual care by being both more effective and less costly. | |||||
Kissela and Eckman BMC Neurology 2008 8:17 doi:10.1186/1471-2377-8-17 |
|||||